Ninety patients were included, but one tumour was reclassified as rhabdomyosarcoma and one suspicion of relapse was dropped. Four patients dropped out due to treatment side effects (tumour burden and comorbidity did not differ from remaining patients).
In the final analysis, 84 patients were included: 40 seminomas (S) and 44 non-seminomas (NS). The median age was 33 years [IQR 28-43 years], median weight was 85 kg [IQR 78-95 kg] and median height was 181 cm [IQR 180-185 cm].
Thirty-seven patients had primary metastatic TC (S 11, NS 26) and 47 relapsed during stage I surveillance (S 29, NS 18). Biopsies confirmed diagnosis in 47 patients (S 32, NS 15) and were inconclusive in two patients (NS 2). In 35 patients, no biopsy was performed (S 8, NS 27). The median time from diagnosis to relapse was seven months [IQR 4-14 months] (S eight months [IQR 6-15 months], NS four months [IQR 2-10 months]). Sixty-seven patients received chemotherapy (S 23, NS 44) and 17 received radiotherapy (S 17). Eleven patients were operated for residual tumour after chemotherapy (8 teratomas, 1 embryonal carcinoma, 1 rhabdomyosarcoma and 1 pure necrosis).
By September 13th 2021, two patients had died (of pneumonia after 5 months and of rhabdomyosarcoma-component after 25 months). Two patients emigrated. The median follow-up time was 29 months [IQR 18-41 months].
Pre-treatment MRI and CT were a median of 5 days apart [IQR 0-18 days] and the post-treatment MRI and CT were a median of 0 days apart [IQR 0-0 days]. The median time between pre- and post-treatment MRI was 63 days [IQR 59-84 days] (chemotherapy 63 days [IQR 58-69 days], radiotherapy 116 days [IQR 112-122 days]). Twenty-two CTs were derived from PET-CT. No adverse reactions to imaging occurred. Only few comorbidities were visible on imaging.
On patient level, malignancy was found in 80 patients by CT and in 79 patients by MRI. Compared to CT, MRI had 98% sensitivity (95% CI 91-100%) and 75% specificity (95% CI 19-99%). One MRI was false positive and two MRIs were false negative. Details table 2A and 3, image examples Fig 1.
Table 2
Contingency tables of results with sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy incl. 95% confidence intervals.
Computed tomography (CT). Magnetic resonance imaging (MRI).
A Patient level, post-treatment MRI vs. post-treatment CT
|
|
Post-treatment CT
|
|
Sensitivity
|
98% (91-100%)
|
Post-treatment MRI
|
No malignancy
|
Malignancy
|
Sum
|
Specificity
|
75% (19-99%)
|
No malignancy
|
3
|
2
|
5
|
PPV
|
99% (93-100%)
|
Malignancy
|
1
|
78
|
79
|
NPV
|
60% (15-95%)
|
Sum
|
4
|
80
|
84
|
Accuracy
|
97% (90-99%)
|
B Lesion level, pre- vs. post-treatment CT
|
|
Post-treatment CT
|
|
Sensitivity
|
98% (96-100%)
|
Pre-treatment CT
|
Benign
|
Malignant
|
Sum
|
Specificity
|
88% (78-95%)
|
Benign
|
60
|
5
|
65
|
PPV
|
97% (94-99%)
|
Malignant
|
8
|
251
|
259
|
NPV
|
92% (83-98%)
|
Sum
|
68
|
256
|
324
|
Accuracy
|
96% (93-98%)
|
C Lesion level, pre- vs. post-treatment MRI
|
|
Post-treatment MRI
|
|
Sensitivity
|
99% (97-100%)
|
Pre-treatment MRI
|
Benign
|
Malignant
|
Sum
|
Specificity
|
78% (69-86%)
|
Benign
|
78
|
4
|
82
|
PPV
|
93% (89-96%)
|
Malignant
|
22
|
286
|
308
|
NPV
|
95% (88-99%)
|
Sum
|
100
|
290
|
390
|
Accuracy
|
93% (90-96%)
|
D Lesion level, post-treatment MRI vs. post-treatment CT
|
|
|
Post-treatment CT
|
|
Sensitivity
|
96% (94-99%)
|
Post-treatment MRI
|
Benign
|
Malignant
|
Sum
|
Specificity
|
87% (69-96%)
|
Benign
|
26
|
8
|
34
|
PPV
|
98% (95-100%)
|
Malignant
|
4
|
200
|
204
|
NPV
|
77% (59-89%)
|
Sum
|
30
|
208
|
238
|
Accuracy
|
95% (91-97%)
|
E Patient level, lungs, post-treatment MRI vs. post-treatment CT
|
|
Post-treatment CT
|
|
Sensitivity
|
82% (48-98%)
|
Post-treatment MRI
|
No malignancy
|
Malignancy
|
Sum
|
Specificity
|
88% (78-94%)
|
No malignancy
|
26
|
8
|
34
|
PPV
|
50% (26-74%)
|
Malignancy
|
5
|
199
|
204
|
NPV
|
97% (90-100%)
|
Sum
|
31
|
207
|
238
|
Accuracy
|
87% (78-93%)
|
F Lesion level, lungs, post-treatment MRI vs. post-treatment CT
|
|
Post-treatment CT
|
|
Sensitivity
|
96% (80-100%)
|
Post-treatment MRI
|
Benign
|
Malignant
|
Sum
|
Specificity
|
50% (1.3-99%)
|
Benign
|
1
|
1
|
2
|
PPV
|
96% (80-100%)
|
Malignant
|
1
|
24
|
25
|
NPV
|
50% (1.3-99%)
|
Sum
|
2
|
25
|
27
|
Accuracy
|
93% (76-99%)
|
Table 3
Lesion level disagreement between post-treatment magnetic resonance imaging (MRI) and post-treatment computed tomography (CT). Patient level disagreement indicated by *. False positive (FP). False negative (FN).
No.
|
|
Region
|
MRI
|
CT
|
Subsequent imaging
(months after diagnosis of metastatic disease)
|
3
|
FP
|
Lung
|
Right side, Likert 4
|
Postinfectious, right side, Likert 1
|
CT after 9, 16 and 40 months without signs of lung metastasis.
|
75
|
FN
|
Lung
|
Left side, 5 mm, Likert 4
|
Left side, 2 mm, Likert 2
|
CT after 5 and 8 months without signs of lung metastasis.
|
10
|
FN
|
Retroperi-toneum (aorta)
|
Several small, 6 mm, Likert 4
|
By left psoas, 6 mm, Likert 2
|
Unchanged on CT after 10, 16 and 40 months.
|
14
|
FN
|
Retroperi-toneum (aorta)
|
By vena cava, 9 mm, Likert 4
|
By vena cava, 9 mm, Likert 2
|
CT after 15 months without signs of retroperitoneal metastasis.
|
19
|
FN
|
Retroperi-toneum (aorta)
|
Several small, not measurable, Likert 3
|
Left side, 8 mm, Likert 2
|
Unchanged on CT after 10 and 14 months.
|
23*
|
FN
|
Retroperi-toneum (aorta)
|
Between vena cava and aorta, 8 mm, Likert 4
|
Several small, not measurable, Likert 2
|
CT after 9 and 15 months without signs of retroperitoneal metastasis.
|
26*
|
FN
|
Retroperi-toneum (aorta)
|
Between vena cava and aorta, 22 mm, Likert 4
|
Between vena cava and aorta, 12 mm, Likert 2
No restrictive diffusion
|
CT after 10 months with additional size reduction to 9 mm.
CT after 16 and 27 months without signs of retroperitoneal metastasis.
|
42
|
FP
|
Retroperi-toneum (aorta)
|
Left side, 10 mm, Likert 4
|
Several small on left side, not measurable, Likert 1
|
Unchanged on CT after 9, 10, 13 and 17 months
|
58*
|
FP
|
Retroperi-toneum (aorta)
|
In front of vena cava, 8 mm, Likert 3
|
-
(lesion level comparison not possible)
|
CT after 8 and 14 months without signs of retroperitoneal metastasis
|
61
|
FP
|
Retroperi-toneum (aorta)
|
Between vena cava and aorta, not measurable, Likert 3
|
Between vena cava and aorta, 5 mm, Likert 2
|
A persistent 12 mm malignant lymph node removed after 5 months. Pathology: teratoma.
CT after 6 and 11 months without signs of retroperitoneal metastasis.
|
69
|
FN
|
Retroperi-toneum (aorta)
|
Right side, 6 mm, Likert 4
|
Right side, 6 mm, Likert 2
|
Discrete size progression on both CT after 4 and 7 months, up to 8 mm. No clinical suspicion of new metastasis.
|
78
|
FP
|
Retroperi-toneum (aorta)
|
Left side, 7 mm, Likert 3
|
Left side, 8 mm, Likert 1
|
CT after 6 and 9 months without signs of retroperitoneal metastasis.
|
61
|
FN
|
Groin
|
Left side, 7 mm, Likert 3
|
Left side, 10 mm, Likert 2
|
CT after 3, 6 and 11 months without signs of metastasis in the groin.
|
CT described 71 benign lesions (median 1 per patient [IQR 0-5], median size 6 mm [IQR 5-8 mm]) and 256 malignant lesions (median 2 per patient [IQR 0-16], median size 12 mm [IQR 9-19 mm]). MRI described 106 benign lesions (median 2 per patient [IQR 0-6], median size 8 mm [IQR 6-11 mm]) and 302 malignant lesions (median 3 per patient [IQR 0-19], median size 13 mm [IQR 10-19 mm]). The majority of malignant lesions were located in the retroperitoneum and lungs (table 4).
Table 4
Number and Likert score of recorded lesions in each region for and post-treatment magnetic resonance imaging (MRI) and post-treatment computed tomography (CT). Likert scale: 1 benign, 2 probably benign, 3 probably malignant, 4 malign. Lesions too small for measurement are not included.
|
Lung
|
Supra-clavicular
|
Media-stinum
|
Retroperi-toneum (aorta)
|
Retroperi-toneum
(iliac)
|
Groin
|
Other lymph nodes
|
Other
|
|
MRI
|
CT
|
MRI
|
CT
|
MRI
|
CT
|
MRI
|
CT
|
MRI
|
CT
|
MRI
|
CT
|
MRI
|
CT
|
MRI
|
CT
|
1
|
7
|
15
|
1
|
2
|
12
|
5
|
7
|
5
|
1
|
1
|
4
|
8
|
3
|
6
|
18
|
6
|
2
|
5
|
6
|
3
|
1
|
5
|
3
|
13
|
7
|
6
|
1
|
6
|
0
|
9
|
0
|
6
|
5
|
3
|
9
|
3
|
5
|
2
|
1
|
1
|
25
|
15
|
5
|
3
|
0
|
2
|
2
|
0
|
2
|
2
|
4
|
39
|
30
|
6
|
3
|
17
|
13
|
162
|
157
|
23
|
23
|
3
|
0
|
1
|
0
|
2
|
2
|
Sum
|
60
|
54
|
15
|
8
|
35
|
22
|
207
|
184
|
35
|
28
|
13
|
10
|
15
|
6
|
28
|
15
|
When comparing pre-treatment scan with post-treatment scan in the same modality, CT had 98% sensitivity (95% CI 96-100%) and 88% specificity (95% CI 78-95%), whereas MRI had 99% sensitivity (95% CI 97-100%) and 78% specificity (95% CI 69-86%). Details table 2B-C.
The difference between CT and MRI sensitivities was 0.57% (95% CI -1.4-2.5%) and thus MRI was non-inferior to CT in detecting TC metastasis.
In total, 238 lesions were described on both CT and MRI. The median difference in pre-treatment
size on CT and MRI was 0 mm [IQR -3-1 mm]. Directly compared to CT on lesion level, MRI had 96% sensitivity (95% CI 94-99%) and 87% specificity (95% CI 69-92%). Four lesions were false positive on MRI: a lung lesion and three lymph nodes <10 mm. Eight lesions were false negative on MRI: a lung lesion, six lymph nodes <10 mm and a 12 mm lymph node without restrictive diffusion. Details table 2D and 3, image examples Fig. 1-2.
In total, 259 lesions were described by one modality only. Different selection in regions with >5
lesions accounted for 72 lesions. In general, the remaining lesions were <10 mm and located in the retroperitoneum or lungs.
Lung metastases were described by CT in 11 patients and by MRI in 18 patients. On patient level compared to CT, MRI had 82% sensitivity (95% CI 48-98%) and 88% specificity (95% CI 78-94%) in detecting lung metastases. In total, 87 lung lesions were described, but only 27 were described by both modalities. On lesion level compared to CT, MRI had 96% sensitivity (95% CI 80-94%) and 50% specificity (95% CI 1.3-99%) in detecting lung metastases. Details table 2E-F.
In one patient, Th12 invasion of a retroperitoneal conglomerate was only visible on MRI. In another patient, a liver lesion disappeared between the pre- and post-treatment scans. Although described as benign before treatment by both, neither CT nor MRI could exclude a liver metastasis. Both findings lead to relevant clinical risk stratification and treatment (image examples Fig. 2).
Eleven patients were operated for residual tumour. In ten patients, the residual tumour was visible on both CT and MRI. In the last patient, a four mm necrotic lesion was described by CT without a corresponding lesion described by MRI (teratoma removed five months after post-treatment scans).
AUC for ROC curves was 0.97 for pre- vs. post-treatment CT, 0.96 for pre- vs. post-treatment MRI and 0.95 for post-treatment MRI vs. post-treatment CT.
The interobserver agreement was substantial between CT and MRI (kappa 0.78).